Possible delayed onset of osteonecrosis of the jaw in association with zoledronic acid

Journal of Clinical Pharmacy and Therapeutics

Volumn 32, Issue 6, 2007, Pages 651-654

  Borras Blasco J ^a   Rosique Robles, D ^a   Giner Marco, V ^a   Galan Brotons, A ^a   Castera E ^a   Costa, S ^b  

^a HOSPITAL DE SAGUNTO   (Spain)

^b HOSPITAL QUIRÓN   (Spain)

Author keywords

Adverse drug reaction; Bisphosphonates; Jaw; Osteonecrosis; Zoledronic acid

Indexed keywords

AMOXICILLIN; CARBOPLATIN; CHLORHEXIDINE; DOCETAXEL; ERLOTINIB; GEMCITABINE; IRINOTECAN; MITOMYCIN C; PACLITAXEL; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; BONE NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; HUMAN; JAW DISEASE; LUNG CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; RISK FACTOR; SKIN MANIFESTATION; TOOTH EXTRACTION;

DIPHOSPHONATES; HUMANS; IMIDAZOLES; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS; TIME FACTORS;

EID: 36248947947     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2007.00845.x     Document Type: Article

References (15)

1. Cohen SB (2004) An update on bisphosphonates. Current Rheumatology Reports, 6, 9 65.
2. Li WW, Kendler DL (2004) Pharmaceutical care and community pharmacists' understanding of bisphosphonate dosing information. Journal of Clinical Pharmacy and Therapeutics, 29, 531 536.
3. Borras Blasco J, Rosique Robles D, Giner Marco V et al. (2006) Zoledronate-related maxillary osteonecrosis. Farmacia hospitalaria, 30, 197 199.
4. Changes to the precautions and post-marketing experience sections of Aredia (pamidronate disodium) injection and Zometa (zoledronic acid) injection prescribing information related to osteonecrosis of the jaw (2004) (package inserts) (accessed 16 June 2005, available at http://www.novartis.com).
5. Woo SB, Hellstein JW, Kalmar JR (2006) Bisphosphonates and osteonecrosis of the jaws. Annals of Internal Medicine, 144, 753 756.
6. Mashiba T, Mori S, Burr DB et al. (2005) The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. Journal of Bone and Mineral Metabolism, 23, 36 42.
7. Whyte MP, Wenkert D, Clements KL et al. (2003) Bisphosphonate- induced osteopetrosis. New England Journal of Medicine, 349, 457 463.
8. Krueger CD, West PM, Sargent M et al. (2007) Bisphosphonate-induced osteonecrosis of the jaw. Annals of Pharmacotherapy, 41, 276 284.
9. Bamias A, Kastritis E, Bamia C et al. (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. Journal of Clinical Oncology, 23, 8580 8587.
10. Reid IR, Brown JP, Burckhardt P et al. (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New England Journal of Medicine, 346, 653 661.
11. Migliorati CA (2005) Bisphosphonate-associated oral osteonecrosis. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics, 99, 135.
12. Ruggiero SL, Mehrotra B, Rosenberg TJ et al. (2004) Osteonecrosis of the jaws associated with the use of Bisphosphonates: a review of 63 cases. Journal of Oral and Maxillofacial Surgery, 62, 527 534.
13. Novartis Europharm Limited (2004) Zometa: summary of product characteristics (online). Available at http://www.emea.eu.int/humandocs/Humans/ EPAR/zometa/zometa.
14. Bilezikian JP (2006) Osteonecrosis of the jaw - do bisphosphonates pose a risk? New England Journal of Medicine, 355, 2278 2281.
15. Naranjo CA, Busto U, Sellers EM et al. (1981) A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics, 30, 239 245.